Development asset linked to Arbutus Biopharma in public FDA and regional records.
biotech · Chronic Hepatitis b · Hepatitis B, Chronic · ABUS
Arbutus Biopharma
Arbutus Biopharma Corp
Arbutus Biopharma drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
701 Veterans Circle, Warminster, Pennsylvania 18974, US HQ
49 Employees
Public company Type
ABUS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 701 Veterans Circle, Warminster, Pennsylvania 18974, US
- Employees
- 49
- Programs
- 13
- Drugs
- 7
- Patents
- 56
Arbutus Biopharma pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Arbutus Biopharma drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Arbutus Biopharma in public FDA and regional records.
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
Development asset linked to Arbutus Biopharma in public FDA and regional records.
-
Development asset linked to Arbutus Biopharma in public FDA and regional records.
-
Development asset linked to Arbutus Biopharma in public FDA and regional records.